- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03666923
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
January 20, 2020 updated by: ThromboGenics
A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-687 for the Treatment of Diabetic Macular Edema (DME)
This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85053
- Retina Consultants of Arizona
-
-
Florida
-
Winter Haven, Florida, United States, 33880
- Center for Retina and Macular Disease
-
-
Indiana
-
Indianapolis, Indiana, United States, 46290
- Midwest Eye Institute
-
-
Nevada
-
Reno, Nevada, United States, 89502
- Sierra Eye Associates
-
-
South Carolina
-
West Columbia, South Carolina, United States, 29169
- Palmetto Retinal Center
-
-
Texas
-
Abilene, Texas, United States, 79606-1224
- Retina Research Institute of Texas
-
McAllen, Texas, United States, 78503
- Valley Retina Institute, PA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female aged 18 years or older
- Type 1 or type 2 Diabetes Mellitus
- Central-involved DME with central subfield thickness of ≥ 320µm on Spectralis® spectral domain optical coherence tomography (SD-OCT) or ≥ 305µm on non-Spectralis SD-OCT, in the study eye
- Best-corrected visual acuity (BCVA) ≤ 62 and ≥ 23 ETDRS letter score in the study eye
- Written informed consent obtained from the subject prior to screening procedures
Exclusion Criteria:
- Macular edema due to causes other than DME
- Concurrent disease in the study eye, other than central-involved DME, that could compromise BCVA, require medical or surgical intervention during the study period or could confound interpretation of the results
- Any condition that could confound the ability to detect a change in central subfield thickness in the study eye
- Previous confounding treatments / procedures, or expected to require confounding treatments / procedures at any time during the study period
- Presence of neovascularization at the disc (NVD) in the study eye
- Uncontrolled glaucoma in the study eye
- Any active ocular / intra-ocular infection or inflammation in either eye
- Poorly controlled Diabetes Mellitus
- Uncontrolled hypertension
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: THR-687 dose level 1
Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 1
|
single intravitreal injection of THR-687 dose level 1
|
Experimental: THR-687 dose level 2
Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 2
|
single intravitreal injection of THR-687 dose level 2
|
Experimental: THR-687 dose level 3
Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 3
|
single intravitreal injection of THR-687 dose level 3
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of dose-limiting toxicities up to the Day 14 visit
Time Frame: From Day 0 up to Day 14
|
From Day 0 up to Day 14
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of systemic and ocular adverse events including serious adverse events up to the end of the study
Time Frame: From Day 0 up to Day 84
|
From Day 0 up to Day 84
|
Occurrence of laboratory abnormalities up to the end of the study
Time Frame: At Screening, Day 1, Day 7, Day 28 and Day 84
|
At Screening, Day 1, Day 7, Day 28 and Day 84
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Department, ThromboGenics Inc. A subsidiary of Oxurion NV.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 17, 2018
Primary Completion (Actual)
November 20, 2019
Study Completion (Actual)
November 20, 2019
Study Registration Dates
First Submitted
September 7, 2018
First Submitted That Met QC Criteria
September 7, 2018
First Posted (Actual)
September 12, 2018
Study Record Updates
Last Update Posted (Actual)
January 22, 2020
Last Update Submitted That Met QC Criteria
January 20, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- THR-687-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on THR-687 dose level 1
-
OxurionTerminatedDiabetes Mellitus | Diabetic Retinopathy | Diabetic Macular EdemaLatvia, Lithuania, United States, Hungary, Estonia
-
ThromboGenicsCompletedDiabetes Mellitus | Diabetic Retinopathy | Diabetic Macular EdemaUnited States
-
OxurionCompletedDiabetes Mellitus | Diabetic Retinopathy | Diabetic Macular EdemaUnited States, France, United Kingdom, Spain, Germany, Italy, Slovakia, Czechia
-
Ehab L AtallahRecruitingAcute Myeloid Leukemia | T Cell Lymphoblastic Lymphoma | T Cell Acute Lymphoblastic LeukemiaUnited States
-
Anagram Therapeutics, Inc.RecruitingExocrine Pancreatic InsufficiencyUnited States
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
University of ChicagoRecruitingLymphoma | Hodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
Baylor College of MedicineUniversity of Texas, Southwestern Medical Center at DallasCompletedLeukemia | CancerUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedLeukemia | Leukemia, B-Cell, ChronicUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisLinKinVaxRecruitingHead and Neck Carcinoma | Adult DiseaseFrance